What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially report Amgen's unaudited financial results for the third quarter and the first nine months of 2017, as well as its financial position as of September 30, 2017. This is done by furnishing a press release containing these details.

Why does Amgen present non-GAAP financial measures?

Amgen presents non-GAAP financial measures because it believes they offer valuable supplementary information to investors. These measures are intended to enhance the overall understanding of the company's financial performance and future prospects by facilitating comparisons of ongoing business operations across different periods, excluding the impact of certain non-operational or variable items.

What specific items does Amgen exclude when calculating its non-GAAP financial measures?

Amgen typically excludes acquisition-related expenses (such as the amortization of purchased intangible assets), net charges related to its restructuring initiatives, and expenses from significant legal judgments or settlements. The company believes excluding these items provides a more meaningful evaluation of its current operating performance.

Where can I find the detailed financial results and reconciliations between GAAP and non-GAAP figures?

The detailed financial results and the necessary reconciliations between non-GAAP and the most directly comparable GAAP financial measures are provided in the press release dated October 25, 2017, which is furnished as Exhibit 99.1 to this 8-K filing.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on October 25, 2017, to report its unaudited financial results for the three and nine months ended September 30, 2017. The filing primarily furnished a press release detailing these results and the company's financial position. A key aspect of this report is Amgen's use of non-GAAP financial measures, which it believes provide investors with enhanced understanding and facilitate comparisons of ongoing business performance. These non-GAAP measures, including non-GAAP earnings per share, operating income, and net income, exclude items such as acquisition-related expenses (primarily amortization of purchased intangibles), restructuring costs, and unusual legal settlements. Amgen also presented Free Cash Flow (FCF) as a measure of liquidity. Investors should note that these non-GAAP figures are supplementary and should be reviewed alongside the company's GAAP results, with reconciliations provided in the furnished press release.

Key Highlights

1Amgen reported its Q3 and year-to-date financial results for the period ending September 30, 2017.
2The company furnished a press release detailing its unaudited results and financial position.
3Amgen utilized and explained its use of various non-GAAP financial measures to provide supplemental performance insights.
4Key non-GAAP adjustments include acquisition-related expenses (amortization of intangibles), restructuring costs, and legal settlements.
5Free Cash Flow (FCF) was presented as an additional liquidity metric.
6Reconciliations between GAAP and non-GAAP measures are available in the furnished press release (Exhibit 99.1).
7The information furnished under Item 2.02 is not considered 'filed' for certain SEC liability purposes.

AMGEN INC 8-K Report, Financial Results (Oct 25, 2017)

Summary

Key Highlights

Frequently Asked Questions